Respiratory Research

Table 4 Adjusted annual direct and indirect costs

From: Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients

Adjusted mean annual costs (€)
Direct costs	Total	Outpatient costs	Inpatient costs	Medication costs	Other costs
% zero costs	0%	0%	62%	0%	56%
Group
A	7460 [7026 – 7924]	937 [902 – 973]	3586 [3201 – 4010]	2522 [2381 – 2663]	566 [513 – 628]
B1	7117 [6029 – 8392]	2570 [2256 – 2866]	1715 [740 – 3076]	2144 [1903 – 2409]	777 [529 – 1049]
B2	6099 [4288 – 8256]	1061 [763 – 1414]	2338 [561 – 5288]	1805 [1388 – 2261]	876 [319 – 1659]
Adjusted mean annual costs (€)
Indirect costs		Human capital approach		Friction costs approach
% zero costs		26%		72%
Group
A		19,583 [18,451 – 20,803]		981 [839 – 1138]
B1		18,813 [13,632 – 24,716]		1276 [608 – 2181]
B2		16,171 [6194 – 28,316]		1866 [633 – 3764]

A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), B1 = COPD patients with AATD and augmentation therapy (AT), B2 = COPD patients with AATD but without AT
Significant estimates on a level of p < 0.05 are printed bold. Indirect costs only include participants < 65 years of age
Totals direct costs and medication costs do not include AT costs of approximately €72,000

Back to article page

ISSN: 1465-993X

Contact us

General enquiries: journalsubmissions@springernature.com